Celiac Disease (CD) also known as coeliac disease/non-tropical sprue or gluten-sensitive enteropathy, is defined as a chronic, multiple-organ small intestinal immune-mediated enteropathy precipitated by exposure to dietary gluten in genetically predisposed people. It is a serious autoimmune disorder where the ingestion of gluten leads to damage in the small intestine; it is not an allergy caused by gluten.
Celiac Disease Epidemiology Insights
Type-Specific Celiac Disease Diagnosed Prevalence in the United States in 2017Classical – 178,536Non-classical – 343,847Sub-clinical- 138,861
The total prevalent population of Celiac Disease in 2017Germany – 738,357the United Kingdom – 650,676Spain – 421,326 Japan – 65,148
Celiac Disease Epidemiology Segmentation in 7MM from 2017 to 2030
Request for sample pages
Table of contents
1. Key Insights
2. Executive Summary of Celiac Disease (CD)
3. Celiac Disease (CD): Disease Background and Overview
3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis
4. Patient Journey
5. Epidemiology and Patient Population
5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
5.3.1. Celiac Disease (CD) Epidemiology Scenario in the 7MM (2017- 2030)
5.4. United States Epidemiology
5.4.1. Celiac Disease (CD) Epidemiology Scenario in the United States (2017- 2030)
5.5. EU-5 Country-wise Epidemiology
5.5.1. Germany Epidemiology
5.5.1.1. Celiac Disease (CD) Epidemiology Scenario in Germany (2017- 2030)
5.5.2. France Epidemiology
5.5.2.1. Celiac Disease (CD) Epidemiology Scenario in France (2017- 2030)
5.5.3. Italy Epidemiology
5.5.3.1. Celiac Disease (CD) Epidemiology Scenario in Italy (2017- 2030)
5.5.4. Spain Epidemiology
5.5.4.1. Celiac Disease (CD) Epidemiology Scenario in Spain (2017- 2030)
5.5.5. United Kingdom Epidemiology
5.5.5.1. Celiac Disease (CD) Epidemiology Scenario in the United Kingdom (2017-2030)
5.6. Japan Epidemiology
5.6.1. Celiac Disease (CD) Epidemiology Scenario in Japan (2017- 2030)
6. Treatment Algorithm, Current Treatment, and Medical Practices
6.1. Celiac Disease (CD) Treatment and Management
6.2. Celiac Disease (CD) Treatment Algorithm
7. KOL Views
8. Unmet Needs
9. Appendix
9.1. Bibliography
9.2. Report Methodology
10. DelveInsight Capabilities
11. Disclaimer
12. About DelveInsight
Media ContactCompany Name: DelveInsightContact Person: Priya MauryaEmail: Send EmailPhone: +919650213330City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/